Vaxart Inc is a biotechnology company focused on developing oral vaccines based on its proprietary platform technology
The company aims to create innovative vaccines that are not only effective but also easy to administer, eliminating the need for needles. Vaxart's research and development primarily targets infectious diseases, with a particular emphasis on creating solutions for viral infections and other public health challenges. Through its unique oral delivery system, Vaxart strives to enhance patient compliance and broaden access to vaccination, ultimately contributing to global health improvement.
Intrigued by the market activity one hour before the close of the markets on Monday? Uncover the key winners and losers of today's session in our insightful analysis.
Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.
Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project NextGen award are expected to extend the company's cash runway into 2026.
Palo Alto Networks reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.25 by 5.6%. Quarterly sales clocked in at $1.985 billion which beat the analyst consensus estimate of $1.967 billion and represents a 15.33% increase over sales of $1.721 billion from the same period last year.
Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by 172.63% and representing a 223.11% increase over sales of $675,000 from the same period last year.
